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Abstract 
Background: Current therapies for organophosphate poisoning involve administration of oximes, such as pralidox-
ime (2-PAM), that reactivate the enzyme acetylcholinesterase. Studies in animal models have shown a low concentra-
tion in the brain following systemic injection.
Methods: To assess 2-PAM transport, we studied transwell permeability in three Madin-Darby canine kidney (MDCKII) 
cell lines and stem cell-derived human brain microvascular endothelial cells (BC1-hBMECs). To determine whether 
2-PAM is a substrate for common brain efflux pumps, experiments were performed in the MDCKII-MDR1 cell line, 
transfected to overexpress the P-gp efflux pump, and the MDCKII-FLuc-ABCG2 cell line, transfected to overexpress the 
BCRP efflux pump. To determine how transcellular transport influences enzyme reactivation, we developed a modi-
fied transwell assay where the inhibited acetylcholinesterase enzyme, substrate, and reporter are introduced into the 
basolateral chamber. Enzymatic activity was inhibited using paraoxon and parathion.
Results: The permeability of 2-PAM is about 2 × 10−6 cm s−1 in MDCK cells and about 1 × 10−6 cm s−1 in BC1-
hBMECs. Permeability is not influenced by pre-treatment with atropine. In addition, 2-PAM is not a substrate for the 
P-gp or BCRP efflux pumps.
Conclusions: The low permeability explains poor brain penetration of 2-PAM and therefore the slow enzyme 
reactivation. This elucidates one of the reasons for the necessity of sustained intravascular (IV) infusion in response to 
organophosphate poisoning.
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
The blood–brain barrier (BBB) is a dynamic system 
responsible for maintaining homeostasis by regulat-
ing the chemical environment, immune cell transport, 
and the entry of toxins into the CNS [1–3]. Neurotox-
ins are microorganisms, viruses, bacterial toxins, and 
chemicals that disrupt neurological function [2, 4]. 
Organophosphates (OPs) are a class of chemical neuro-
toxicants comprised of a central phosphate surrounded 
by electronegative atoms, such as oxygen and sulfur. 
While widely used as insecticides, nerve agents such as 
sarin and VX, are also organophosphates [5]. In the brain 
and body, organophosphates persistently bind to the 
active site of acetylcholinesterase, blocking breakdown of 
the neurotransmitter acetylcholine [6, 7].
Organophosphate poisoning is usually treated with 
oximes, such as pralidoxime (2-PAM), that reactivate 
acetylcholinesterase [7]. The FDA protocol for organo-
phosphate poisoning involves immediate intramuscular 
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(IM) injection followed by intravascular (IV) administra-
tion [6, 8]. IM injection of 2-PAM is usually co-adminis-
tered with atropine and/or diazepam. Typical IV dosing 
of 2-PAM, depending on symptoms and exposure path-
way, involves administration of 1  g in 100  mL−1 saline 
over 15–30  min followed by continuous infusion of 
500 mg h−1 (about 700 µM in blood) [6, 7].
2-PAM is an ionic molecule and hence the permeability 
across the blood–brain barrier has been assumed to be 
very low [9, 10]. Clinical trials have shown that 2-PAM 
is rapidly cleared from the body [11, 12], highlighting the 
need for continuous infusion to maintain a therapeutic 
dose [11, 13–15]. Based on animal studies, the minimum 
effective concentration in blood is reported to be around 
4 mg L−1 (about 30 µM) [9, 15].
Therefore, to assess transport into the brain we stud-
ied permeability of 2-PAM in four cell lines: MDCKII, 
MDCKII-MDR1, MDCKII-FLuc-ABCG2, and BC1-
hBMECs. Madin-Darby canine kidney epithelial cells 
(MDCKs) are widely used for in vitro assessment of brain 
penetration and the permeability values for a wide range of 
solutes have been reported [16]. The MDCKII-MDR1 cell 
line is transfected to express the human P-gp efflux pump, 
and the MDCKII-FLuc-ABCG2 line is transfected to over-
express BCRP efflux pump. Human brain microvascular 
endothelial cells (BC1-hBMECs) are derived from human-
induced pluripotent stem cells (hiPSCs) [17–19].
Materials
Cell lines
MDCKII and MDCKII-MDR1 cells were obtained from 
the Netherlands Cancer Institute (NKI) [20]. Follow-
ing NKI’s protocol, cells were cultured in DMEM (High 
Glucose, GlutaMAX) with 10  % Fetal Bovine Serum 
(FBS, ATCC, Manassas, VA, USA), and 1  % penicillin–
streptomycin (ATCC). MDCKII/ABCG2 cells express-
ing ABCG2/BCRP were provided by the Pomper Group 
(JHU). MDCKII cells were transfected with pGL4.16 
[luc2cp/Hygro] (Promega, Madison, WI, USA) [21, 22]. 
Cells were maintained in MEM-l-glutamine (Life Tech, 
Carlsbad, CA, USA), 10  % FBS HI, 1  mg  mL−1 G418 
(Geneticin, Life Tech), and 100  µg  mL−1 Hygromycin B 
(Life Tech) [22].
Human brain microvascular endothelial cells (BC1-
hBMECs) were derived from iPSCs, based on a protocol 
reported by Lippmann et al. [17, 18]. Briefly, BC1 iPSCs 
[23] were cultured for 4 days in TeSR-E8 Basal Medium 
(05940, Stem Cell Technologies, Vancouver, BC, Can-
ada) on growth factor-reduced Matrigel, 40  µg  mL−1 
(354230, Fisher Scientific, Pittsburgh, PA, USA) [19]. 
Once cells formed substantial colonies, they were 
placed in UM/F- unconditioned media (DMEM/F12, 
20  % KOSR, 0.5  % l-glutamine, 1  % NEAA, 0.836  µM 
Beta-Mercaptoethanol) for 6 days. For the final 2 days of 
differentiation, the cells were placed in endothelial cell 
serum-free media (EC, 1 % human platelet poor-derived 
serum, 20 ng mL−1 bFGF) with 10 µM all trans retinoic 
acid (Sigma, St. Louis, MO, USA) to promote preferential 
growth of the BC1-hBMECs. The cells were then sub-cul-
tured onto the transwell supports coated with collagen 
IV (100  μg  mL−1; Sigma) and fibronectin (50  μg  mL−1; 
Sigma) and cultured for two more days prior to perform-
ing permeability experiments [19]. Characterization of 
the BC1-hBMEC cells has been reported elsewhere [19].
Permeability measurements
2‑PAM
MDCK cells were seeded on transwells (24 well; PE; 
0.33 cm2 area; 0.4 µm pore diameter, Corning, Corning, 
NY, USA) coated with collagen I (rat tail, 10  µg  cm−2, 
Corning) at a density of 6 ×  105 cells cm−2. Permeabil-
ity experiments were performed 4  days after seeding. 
The medium was changed 2 h before the experiment and 
transepithelial electrical resistance (TEER) was measured 
before all experiments (Endohm/EVOM2). For MDCK 
cells, permeability measurements were performed if 
the TEER was  ≥90  Ω  cm2 (see Additional file  1: Table 
S1:  TEER values for transwell experiments) [24, 25]. To 
confirm the integrity of the MDCK monolayers, the per-
meability of Lucifer yellow, 100 µM, was measured for up 
to 2 h. In all cases the permeability was ≤1 × 10−6 cm s−1: 
0.71 ± 0.34 × 10−6 cm s−1 (MDCKII), 0.38 ± 0.20 × 10−6 
cm s−1 (MDCKII-MDR1), and 0.46 ± 0.21 × 10−6 cm s−1 
(MDCKII-FLuc-ABCG2). The measured permeability for 
Lucifer yellow under the same conditions in transwells 
without cells, was 4.35 × 10−5 cm s−1.
All experiments with MDCK cells were performed in 
Hank’s balanced salt solution (HBSS) with 10 mM HEPES 
(Sigma) and 15 mM glucose (Sigma), pH 7.4. After incu-
bation in media for 2 h, cell monolayers were immersed 
in fresh HBSS for 30 min to remove any traces of media. 
Then 100  µM or 10  µM 2-PAM (pralidoxime chloride, 
Sigma) in HBSS was pipetted into either the apical or 
basolateral chamber, with HBSS on the receiving side. 
Cell monolayers with test solutes were incubated at 37 °C 
with 5 % CO2 on a rocker to ensure good mixing.
For experiments with BC1-hBMECs, cells were seeded 
on transwells (24 well; PE; 0.33  cm2 area; 0.4  µm pore 
diameter, Corning) coated overnight with a 50/50 mix-
ture collagen IV (100  μg  mL−1; Sigma) and fibronectin 
(50 μg mL−1; Sigma) at a density of 1 × 106 cells mL−1. 
For BC1-hBMECs, permeability measurements were 
performed with cells that had a TEER of  ≥1500 Ω cm2. 
Experiments were performed in transport buffer (distilled 
Millipore water with 0.12  M NaCl, 25  mM NaHCO3, 
3 mM KCl, 2 mM MgSO4, 2 mM CaCl2, 0.4 mM K2HPO4, 
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1  mM HEPES, and 0.1  % human platelet poor-derived 
serum) without the pre-incubation of media or rocking of 
the cells. After 2 days in EC media, 100 µM of 2-PAM in 
transport buffer was pipetted into the apical or basolat-
eral well with transport buffer on the receiving side.
The concentration of 2-PAM was determined by 
HPLC (1260 Infinity HPLC, Agilent, Santa Clara, CA, 
USA) with UV Vis detection at 296  nm. Solvents were 
degassed by sonication for 45 min before use and all sam-
ples were run at room temperature. An isocratic flow of 
44  vol.% acetonitrile (HPLC grade, Chromasolv, Sigma) 
and 56 vol.% ammonium acetate (0.03  M; HPLC grade, 
Sigma), pH 4.5, was used with a PolyCAT A column 
(100 × 2.1 mm, 5 µM, 300 Å, 102CT05-03, Poly LC Inc, 
Columbia, MD, USA) [26]. Calibration curves were con-
structed from standard solutions with concentrations of 
0.1, 1, 10 and 100 µM. Due to the simplicity of the proce-
dure, no internal standard was used.
2‑PAM/atropine
To assess whether atropine, which is often co-adminis-
tered with 2-PAM, modulates the transport of 2-PAM 
we performed experiments where MDCK cells were pre-
treated with atropine. After 2 h incubation in media, and 
30  min rinse in HBSS, MDCKII monolayers were pre-
treated with 1  µM atropine for 30  min, rinsed in HBSS 
for 5 min, and then incubated in 100 µM 2-PAM for per-
meability measurements using the same procedure as 
described above. 2-PAM concentrations were measured 
by HPLC with an isocratic flow of 55 vol.% acetonitrile 
and 45 vol.% ammonium acetate (0.03 M).
Rhodamine 123
To confirm the up-regulation and polarization of P-gp 
efflux pumps to the apical face, we measured the perme-
ability of Rhodamine 123, a known P-gp substrate, across 
MDCKII and MDCKII. MDR1 monolayers [27]. Perme-
ability experiments were performed for 60 min at a con-
centration of 50  µM. The concentration of Rhodamine 
123 (excitation 486 and emission 523) was measured by 
fluorescence (Fluorolog, Horiba Scientific, Edison, NJ, 
USA). Calibration curves were generated over the con-
centration range from 0.001 to 1 µM.
Coupled permeability and acetylcholinesterase 
reactivation
To assess coupled 2-PAM transport and enzyme reactiva-
tion, experiments were performed in a transwell device 
with acetylcholinesterase in the basolateral chamber. 
Confluent monolayers of MDCKII cells were formed 
as described above. Electric eel acetylcholinesterase 
(AChE, 1U or about 1  µL,  >1000  U/mg, Sigma) was 
placed into the basolateral chamber (24 well plate). A 
mixture of Ellman’s reagent (DTNB), final concentration 
300  µM, and acetylthiocholine (ASCh), final concentra-
tion 450 µM, dissolved in HBSS, was introduced into the 
basolateral chamber, to give a final volume of 600 µL. The 
time-dependent activity of the enzyme was determined 
from the absorbance of the DTNB reporter at 412  nm 
using a plate reader (Spectramax M3). Results were nor-
malized to the activity of the uninhibited enzyme, un-
normalized data are provided in the Additional file  1 
(Figure S1: Non-normalized reactivation data).
Inhibition was achieved by incubating the enzyme with 
0.72 mM parathion (PESTANAL-grade, Sigma) or 4.6 µM 
paraoxon (PESTANAL-grade, Sigma) for 20 min prior to 
experiments. In inhibition experiments, the enzyme was 
inhibited with parathion. Paraoxon, a metabolite of par-
athion, is about three orders of magnitude more potent 
as an anticholinesterase inhibitor [28]. The parathion 
concentration was 157-fold higher than the paraoxon 
concentration, reflecting their different activities. For 
reactivation experiments, 2-PAM was introduced into 
either the apical or basolateral chamber in HBSS. Intro-
ducing 2-PAM into the basolateral chamber simulates 
reactivation alone, whereas introduction of 2-PAM into 
the apical chamber simulates coupled trans-endothelial 
transport and reactivation.
Positive control (uninhibited enzyme + substrate)
To assess the kinetics of enzyme interaction with the sub-
strate, uninhibited enzyme (AChE), along with substrate 
(ASCh), and reporter (DTNB) in HBSS were introduced 
into the basolateral chamber. An apical transwell cham-
ber with a monolayer of MDCK cells was located on the 
top of the basolateral chamber to ensure that the control 
was performed in the same way as the other experiments.
Negative control (inhibited enzyme + substrate)
To assess the efficiency of enzyme inhibition, AChE was 
mixed for 20 min with concentrated parathion (0.72 mM 
final concentration) or paraoxon (4.6  µM final concen-
tration) organophosphates (OP). The inhibited enzyme 
(AChE-OP) was then placed in the basolateral chamber 
with substrate (ASCh) and reporter (DTNB) in HBSS. An 
apical transwell chamber was located on the top of the 
basolateral chamber as described above.
Direct interaction of 2‑PAM (inhibited 
enzyme + substrate + reactivator)
To assess the kinetics of direct reactivation of inhibited 
enzyme, 100 µM 2-PAM was introduced in the basolat-
eral chamber with the inhibited enzyme (AChE-OP), 
substrate (ASCh) and reporter (DTNB) in HBSS. An api-
cal transwell chamber was located on the top of the baso-
lateral chamber as described above.
Page 4 of 8Gallagher et al. Fluids Barriers CNS  (2016) 13:10 
Coupled transport of 2‑PAM and reactivation
To evaluate the coupled transport of 2-PAM across a cell 
monolayer and reactivation of inhibited enzyme, 100 µM 
of 2-PAM was introduced into the apical chamber, with 
inhibited enzyme (AChE-OP), reporter (DTNB), and 
substrate (ASCH) in the basolateral chamber.
Statistics
Permeability, activity, and reactivation half-time repre-
sent the mean  ±  standard deviation. Statistical signifi-
cance was determined using a student’s t test (two-tailed 
with unequal variance) with p < 0.01 ** and p < 0.001 ***. 
The average permeability values for the MDCK cell lines 
were calculated from analysis of all of the replicates. Due 
to variations between differentiations, the average per-
meability across the BC1-hBMECs was calculated from 
the average values from each differentiation. Similarly, 
the efflux ratio was calculated from the average value 
obtained from each differentiation.
Results
Permeability of 2‑PAM
To assess the transport of 2-PAM and to determine 
whether 2-PAM is an efflux pump substrate, transwell 
experiments were performed in three cell lines: MDCKII, 
MDCKII-MDR1, MDCKII-FLuc-ABCG2 at concen-
trations of 10 and 100  µM (Table  1; Fig.  1). In 10  µM 
2-PAM, the average apical-to-basolateral permeability 
in MDCKII and MDCKII-MDR1 monolayers was about 
2 × 10−6 cm s−1. The average permeability of MDCKII-
ABCG2 monolayers was slightly lower, 0.83  ×  10−6 
cm s−1, although the difference compared to the MDCKII 
and MDCKII-MDR1 monolayers was not significant. For 
100  µM 2-PAM, the average permeability in MDCKII 
and MDCKII-MDR1 monolayers increased to about 
3 × 10−6 cm s−1; this increase was significant in MDCKII 
cells (p  =  0.05), but not significant in MDCKII-MDR1 
cells. The average permeability in MDCKII-ABCG2 
cells was 0.76 ×  10−6 cm s−1, very close to the value in 
10 µM 2-PAM. The average basolateral-to-apical perme-
ability was very close to the apical-to-basolateral value 
in all three cell lines with no statistical difference. The 
apical-to-basolateral permeability of 2-PAM across the 
stem-cell derived BC1-hBMECs was 1.12 ± 0.80 × 10−6 
cm  s−1, comparable to the permeability across the 
MDCKII cells. The basolateral-to-apical permeability 
(0.49 ± 0.16 × 10−6 cm s−1) was lower (p = 0.05).
Influence of atropine on 2‑PAM permeability
To determine whether atropine, co-administered with 
2-PAM, modulates the permeability of 2-PAM, we 
measured the permeability of 2-PAM following pre-
treatment of the MDCKII monolayer with atropine. The 
permeability of 2-PAM was 2.54 ± 0.33 × 10−6 cm s−1, 
which was not significantly different to the value of 
2.99 ±  1.12 ×  10−6 cm  s−1 obtained without pre-treat-
ment with atropine (Table 1).
Permeability of rhodamine 123
To confirm the polarization of the P-gp efflux pumps to 
the apical surface of the MDCK cells, we measured the 
permeability of 50  µM rhodamine 123, a known sub-
strate for the P-gp efflux pump [27, 29], in MDCKII 
and MDCKII-MDR1 cells (Table  1). The basolateral-to-
apical permeability of rhodamine 123 in MDCKII was 
3.18 × 10−6 cm s−1, with an apical-to-basolateral perme-
ability of 0.30 × 10−6 cm s−1 (p = 0.001), corresponding 
to an efflux ratio of 10.7. For the MDCKII-MDR1 cells, 
the basolateral-to-apical permeability was 4.36  ×  10−6 
cm  s−1, with an apical-to-basolateral permeability of 
0.22 × 10−6 cm s−1 (p = 0.001) corresponding to an efflux 
ratio of 20.3. The basolateral-to-apical permeabilities to 
Table 1 Permeability of  pralidoxime (2-PAM), rhodamine 
123 R123) and  Lucifer yellow (Ly) across  MDCKII, MDCKII-
MDR1, MDCKII-FLuc-ABCG2, and BC1-hBMEC monolayers
A→B represents apical-to-basolateral permeability, and B→A represents 
basolateral-to-apical permeability. Permeability values are reported as 
mean ± standard deviation. The efflux ratio is the ratio of basolateral-to-apical 
permeability divided by the apical-to-basolateral permeability. For MDCK 
cells, permeabilities and efflux ratios were calculated from the total number of 
replicates (N). Data were obtained from at least three independent experiments 
each with two or more replicates. For the BC1-hBMECs, the permeabilities and 
efflux ratios were calculated from the average of each differentiation, where N 
represents the number of independent differentiations
Papp A→B (cm s−1) N Papp B→A (cm s−1) N Efflux 
ratio
100 µM 2-PAM
MDCKII 2.99 ± 1.12 × 10−6 11 2.48 ± 1.30 × 10−6 8 0.82
MDCKII-MDR1 3.01 ± 1.27 × 10−6 8 2.51 ± 1.08 × 10−6 7 0.83
MDCKII-FLuc-
ABCG2
0.76 ± 0.05 × 10−6 7 0.98 ± 0.40 × 10−6 7 1.30
BC1-hBMECs 1.12 ± 0.80 × 10−6
(n = 5)




MDCKII 1.62 ± 0.21 × 10−6 6 1.29 ± 1.76 × 10−6 7 0.80
MDCKII-MDR1 2.03 ± 0.14 × 10−6 8 1.18 ± 0.45 × 10−6 8 0.58
MDCKII-FLuc-
ABCG2
0.83 ± 0.35 × 10−6 7 0.99 ± 0.62 × 10−6 7 1.18
50 µM R123
MDCKII 0.30 ± 0.20 × 10−6 6 3.18 ± 0.60 × 10−6 5 10.7
MDCKII-MDR1 0.21 ± 0.21 × 10−6 12 4.36 ± 0.41 × 10−6 11 20.3
100 µM LY
MDCKII 0.71 ± 0.34 × 10−6 7
MDCKII-MDR1 0.38 ± 0.20 × 10−6 7
MDCKII-FLuc-
ABCG2
0.46 ± 0.21 × 10−6 8
2-PAM atropine
MDCKII 2.54 ± 0.33 × 10−6 7
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rhodamine in MDCKII and MDCKII. MDR1 cells were 
significantly different (p = 0.02) supporting upregulation 
and polarization of P-gp efflux pumps to the apical side of 
the MDCKII.MDR1 cells. Apical-to-basolateral perme-
abilities of 0.83 × 10−6 and 0.89 × 10−6 cm s−1, with cor-
responding efflux ratios of 9 and 115, have been reported 
for transport of 5  µM rhodamine 123 across MDCKII.
MDR1 cells [27, 29]. The reported efflux ratio for rhoda-
mine in BC1-hBMEC cells is approximately 4 [19].
Coupled transport and acetylcholinesterase (AChE) 
reactivation
To assess the coupled transcellular transport and AChE 
reactivation, we performed transwell experiments with 
a monolayer of MDCKII cells and inhibited enzyme in 
the basolateral chamber (Fig.  2a). Acetylcholinester-
ase was inhibited with an organophosphate (parathion 
or paraoxon) for 20  min and then introduced into the 
basolateral chamber of a transwell device, along with 
acetylthiocholine (ASCh) and the colorimetric reporter 
(DTNB). Control experiments were performed to con-
firm the activity of the enzyme and effectiveness of the 
inhibitor.
In the absence of 2-PAM, the activity of the inhibited 
enzyme (AChE-OP) increased very slowly during the 2 h 
experiment (Fig. 2b). When 2-PAM was introduced into 
the basolateral chamber with inhibited enzyme, reacti-
vation occurred much more quickly (Parathion: inhib-
ited enzyme and direct reactivation p < 0.001, Paraoxon: 
inhibited enzyme and direct reactivation p < 0.01). How-
ever, when 2-PAM was introduced into the apical cham-
ber, reactivation of the inhibited enzyme was slowed 
considerably due to the coupled transport and reactiva-
tion (Parathion: direct reactivation and transport reac-
tivation p  <  0.001, paraoxon: direct reactivation and 
transport reactivation p < 0.01).
The activity of the enzyme following transcellu-
lar transport of 2-PAM across MDCKII monolayers 
(3.49  ×  10−4 abs  s−1) was about four fold lower than 
when the inhibited enzyme was directly exposed to 
2-PAM (1.35 × 10−3 abs s−1) (Fig. 2c). Similarly, the half-
time for reactivation of the substrate increased sixfold 




The permeability of 2-PAM was between 1 ×  10−6 and 
2  ×  10−6  cm  s−1 in all three MDCK cell lines, lower 
than for most central nervous system drugs, which typi-
cally have permeabilities greater than 1  ×  10−5 cm  s−1 
[30]. However several CNS drugs have permeabilities 
similar to 2-PAM, including the antipsychotics per-
phenazine (p  =  1.8  ×  10−6 cm  s−1) and fluphenazine 
(p = 3.5 × 10−6 cm s−1), the anti-anxiety drug sertralin 
(Zoloft) (p = 2.1 × 10−6 cm s−1), and the analgesic, mor-
phine (p = 2 × 10−6 cm s−1) [16]. While morphine has 
a low permeability in MDCK cells, the therapeutic dose 
is particularly low [16]. The low permeability of 2-PAM 
explains the reported low concentration in the brain in 
animal studies [10] and the recommended sustained clin-
ical infusion in a clinical setting [6].
MDCK cells are widely used to assess brain penetra-
tion of small molecules. Although MDCK cell lines are 
epithelial in origin and not human, they express tight 
junction proteins, which limit paracellular transport. 
Variants such as MDCKII-MDR1 can be used to deter-
mine whether a solute is an efflux pump substrate. The 
stem cell derived BC1-hBMECs exhibit high transen-
dothelial electrical resistance (TEER  >  1000  Ω  cm2), 
low permeability to solutes such as Lucifer yellow, and 
Fig. 1 a 2-PAM permeability in four different cells lines at a concen-
tration of 100 µM. b 2-PAM permeability of in three different cells lines 
at a concentration of 10 µM. Basolateral-to-apical (red), basolateral-to-
apical (blue). Permeability is reported as mean ± standard devia-
tion. Experiments were performed in HBSS (MDCKII, MDCKII-MDR1, 
MDCKII-ABCG2) or transport buffer (BC1-hBMEC)
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express tight junction proteins (e.g. claudin-5), transport-
ers (e.g. LAT-1), and efflux pumps (e.g. P-gp) [17, 19]. 
The permeability of the stem cell derived BC1-hBMECs 
(p = 1.12 ± 0.80 × 10−6 cm s−1) was slightly lower than 
values obtained in MDCK cells, but in the range that is 
consistent with slow accumulation in the brain.
High permeability values are usually associated with 
small molecular weight and moderate lipophilicity [31, 
32]. While 2-PAM has a molecular weight under 500 Da 
(172  Da), fewer than 5 hydrogen bond donors (1), and 
fewer than 10 hydrogen bond acceptors (2), the charge 
results in a low lipophilicity and hence 2-PAM is not 
expected to have a high permeability.
There was no significant difference between apical-and-
basolateral and basolateral-to-apical permeabilities  in 
MDCK cells, indicating that 2-PAM is not a substrate 
of the P-gp or ABCG2 pumps. To confirm the polar-
ized expression and activity of the P-gp efflux pumps, we 
determined efflux ratios of 10.7 and 20.3 for the MDCKII 
and MDCKII. MDR1 cell lines for the known P-gp sub-
strate rhodamine 123.
Treatment for organophosphate poisoning involves 
co-administration of 2-PAM and atropine. The perme-
ability of 2-PAM was the same in MDCKII cells and cells 
pretreated with atropine, showing that atropine does not 
modulate the permeability of 2-PAM.
Coupled transcellular transport and enzyme reactivation
To study coupled transcellular transport of the neuro-
toxin antidote 2-PAM with enzyme reactivation, we 
developed a modified transwell assay with inhibited 
enzyme (AChE-OP), substrate (ASCh), and reporter 
(DTNB) in the basolateral chamber. When 2-PAM was 
introduced into the apical chamber of the transwell 
device, the activity of the enzyme decreased four fold 
compared to the case where 2-PAM was introduced 
directly into the basolateral chamber. Similarly, the half-
time for reactivation of the enzyme increased six fold 
Fig. 2 a Schematic illustration of the modified transwell assay for measurement of coupled transcellular transport and enzymatic activity, and the 
chemical structure of 2-PAM. b Representative normalized absorbance versus time plots for reactivation of AChE. 1 AChE + ASCh: positive control 
(uninhibited enzyme + substrate). 2 AChE-OP + ASCh: negative control (inhibited enzyme + substrate). 3 AChE-OP + ASCh + 2-PAM: reactivation 
with no transport (inhibited enzyme + substrate + reactivator). 4 2-PAM//AChE-OP + ASCh: transcellular transport + reactivation. c Normalized 
AChE activity (dA/dt) obtained from absorbance versus time curves at the inflection point. The legend provides the details of each experiment.  
d Half-time for AChE reactivation. Data represent mean ± SD. All reactivation experiments were performed in HBSS
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when coupled to transcellular transport. These results 
highlight the difficulty in maintaining a therapeutic dose 
when the permeability is low.
Conclusions
The permeability of the nerve agent reactivator 2-PAM 
is 1 × 10−6 – 2 × 10−6 cm s−1 and is not influenced by 
pre-treatment with atropine. In addition, 2-PAM is 
not a substrate for the P-gp or BCRP/ABCG2 efflux 
pumps. Similar permeability values were obtained for 
human brain microvascular endothelial cells derived 
from induced pluripotent stem cells. In a modified tran-
swell assay to couple transcellular transport and enzyme 
reactivation, we showed that transcellular transport 
decreased enzymatic activity four fold and increased 
the reactivation half-time six fold. The low permeability 
explains poor brain penetration of 2-PAM and the neces-
sity for sustained IV infusion in response to organophos-
phate poisoning.
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